{
  "id": 3777537,
  "title": "Paysign at 17th Annual Midwest IDEAS Conference: growth broadens",
  "url": "https://urgent.news/2026/08/27/paysign-at-17th-annual-midwest-ideas-conference-growth-broadens",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-27T17:03:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/paysign-at-17th-annual-midwest-ideas-conference-growth-broadens-93CH-4879955"
  },
  "original_language": "en",
  "account": "On Thursday, 27 August 2026, Paysign (PAYS) utilized the 17th Annual Midwest IDEAS Conference to showcase a business experiencing dual growth. The company highlighted its plasma payments unit as a market leader, while its patient affordability business was expanding rapidly and contributing significantly to recent revenue increases. Management also addressed potential risks, such as industry oversupply in plasma payments and ongoing pushback from insurers and pharmacy benefit managers in the co-pay market. Despite these challenges, Chief Financial Officer Jeff Baker stated that the company is entering a period of stronger operating leverage and wider margins.\n\nPaysign holds a 45.5% market share in plasma payments, positioning it as the largest provider in the U.S. market. Patient affordability revenue surged in the first half of 2026, with first-half revenue increasing by more than 85% year over year. The company projected 2026 revenue between $114 million and $117 million and Adjusted EBITDA between $35 million and $38 million. Management indicated that 50% of the incremental second-quarter revenue contributed to operating income.\n\nThe company reported no bank debt and over $30 million in unrestricted cash. In 2025, Paysign's revenue was $82 million, up 40.5% from $58.4 million in 2024, and Adjusted EBITDA rose 107% to about $20 million. SG&A expenses grew 31.2%, below the rate of sales growth. Total revenue in 2025 was $82 million, up from $58.4 million in 2024. Adjusted EBITDA was about $19.8 million to $20 million, up 107%. Gross margin was 59.4% and net income was around $5.7 million to $6 million. Diluted EPS was projected at $0.09 to $0.10 for 2025.\n\nFor 2026, the company guided continued growth and margin expansion: total revenue between $114 million and $117 million, Adjusted EBITDA between $35 million and $38 million, gross margin between 60% and 62%, adjusted EBITDA margin between 62% and 63%, net income between $21.5 million and $23 million, and diluted EPS between $0.35 and $0.37.\n\nJeff Baker noted a clear operating inflection in the second quarter, with 50% of each additional dollar dropping to operating income. Paysign serves 561 facilities out of approximately 1,200 in the U.S., managing 8.4 million cardholders, giving it a 45.5% market share. The company's revenue growth of nearly 47% over the last twelve months significantly outpaces many peers in the payments sector, trading at a P/E ratio of approximately 52 and a PEG ratio of just 0.41, suggesting potential attractive valuation relative to its growth trajectory.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Aebi Schmidt at Midwest IDEAS: growth plan leans on synergies",
        "url": "https://urgent.news/2026/08/27/aebi-schmidt-at-midwest-ideas-growth-plan-leans-on-synergies",
        "published": "2026-08-27T16:20:57.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}